Particle.news

American Cancer Society Recommends Proactive, Risk‑Based PSA Screening

The shift aims to cut prostate cancer deaths and late diagnoses by pairing regular blood tests with MRI and biomarker checks before biopsy.

Overview

  • The ACS published the new guideline in CA: A Cancer Journal for Clinicians on November 12, 2026, marking its first proactive screening recommendation since 2010.
  • For average‑risk men the society advises PSA testing every two years from ages 50 to 69 and recommends annual screening from ages 45 to 69 for Black men and those with a strong family history.
  • The guidance requires repeat PSA confirmation and urges use of prostate MRI or validated urine or blood biomarkers to decide whether a biopsy is needed.
  • Men with low‑risk prostate cancer should be offered active surveillance as the first management option to limit unnecessary treatment and harm.
  • Real‑world benefits depend on access to MRI and biomarker tests, insurer coverage, and specialist follow‑up, which could shape how much screening reduces deaths and advanced disease.